Johnson & Johnson's Janssen Biotech Unit Secures US FDA Approval for Multiple Myeloma Treatment
MT Newswires Live
Mar 06
Johnson & Johnson's (JNJ) Janssen Biotech unit received the US Food and Drug Administration's approval for the Tec-Dara drug combination to treat adults with multiple myeloma who have received at least one prior therapy, the health regulator said Thursday.
A late-stage clinical trial showed the combination reduced the risk of the condition worsening or fatality by 83% compared with the usual treatments, the FDA said.
The FDA added that this supporting clinical data also transitioned the standalone Tecvayli medication from an accelerated clearance to a conventional approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.